SESN Sesen Bio Inc.

0.54
0  0%
Previous Close 0.54
Open 0.54
Price To Book -2.26
Market Cap 59,701,903
Shares 109,988,768
Volume 630,221
Short Ratio
Av. Daily Volume 1,015,690
Stock charts supplied by TradingView

NewsSee all news

  1. Sesen Bio Reports Fourth Quarter and Full-Year 2019 Financial Results

    Company on track to complete Vicinium® BLA submission in the second half of 2020 with potential approval in first half of 2021 New market research supports large commercial opportunity Sesen Bio (NASDAQ:SESN), a

  2. Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide Business Update Highlighting Regulatory Progress and Commercial Opportunity for Vicinium®

    Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Dr.

  3. Sesen Bio Announces Changes to the Board of Directors as the Company Advances Toward Commercialization of Vicinium®

    Sesen Bio (Nasdaq: SESN) a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointment of Carrie Bourdow, chief executive officer of Trevena, Inc., and

  4. Sesen Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that it has granted non-statutory stock options to

  5. Sesen Bio Initiates Rolling Submission of BLA for Vicinium to FDA

    Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that on December 6, 2019, the Company initiated the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Rolling BLA filing to be completed 2H 2020.
Vicinium
Non-muscle invasive bladder cancer (NMIBC)

Latest News

  1. Sesen Bio Reports Fourth Quarter and Full-Year 2019 Financial Results

    Company on track to complete Vicinium® BLA submission in the second half of 2020 with potential approval in first half of 2021 New market research supports large commercial opportunity Sesen Bio (NASDAQ:SESN), a

  2. Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide Business Update Highlighting Regulatory Progress and Commercial Opportunity for Vicinium®

    Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Dr.

  3. Sesen Bio Announces Changes to the Board of Directors as the Company Advances Toward Commercialization of Vicinium®

    Sesen Bio (Nasdaq: SESN) a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointment of Carrie Bourdow, chief executive officer of Trevena, Inc., and

  4. Sesen Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that it has granted non-statutory stock options to

  5. Sesen Bio Initiates Rolling Submission of BLA for Vicinium to FDA

    Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that on December 6, 2019, the Company initiated the

  6. Sesen Bio Completes Successful CMC Type B pre-BLA Meeting with FDA

    Company gained FDA alignment on the final content of the BLA Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today

  7. Sesen Bio Reports Third Quarter 2019 Financial Results and Update on Regulatory Activities Related to Vicinium

    On Track for Anticipated Initiation of BLA Submission in December, 2019 Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer,

  8. Sesen Bio Announces Successful Type C Meeting with FDA for Vicinium

    Alignment reached with FDA on post-marketing confirmatory trial design Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer,

  9. Sesen Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured as a presenting company at the H.C.

  10. Sesen Bio Announces CFO Transition as Company Drives Towards Anticipated Initiation of BLA Submission in 4Q 2019

    Company Appoints Monica Forbes as Chief Financial Officer and Kirstin Anderson as Principal Accounting Officer